CB SCIENTIFIC INC - CBSC STOCK NEWS

CB Scientific (OTC PINK:CBSC), a company focused on non-invasive ambulatory cardiac monitoring products, has announced its voluntary delisting from the OTCQB Venture Market. This decision aims to preserve capital for implementing the company's business plan. Importantly, CBSC's common stock will continue trading on the OTC Pink Open Market, allowing shareholders to maintain their ability to trade shares in the public market. The company states that it plans to re-engage an auditor and apply for uplisting when certain milestones are achieved and conditions are appropriate.

CB Scientific (OTCQB: CBSC) has announced an exclusive 5-year distribution agreement with Your Heart Protector Corp. in Canada. This agreement will allow Your Heart Protector to market CBSC's non-invasive cardiac monitoring products and provide related services. The partnership includes developing cloud-based software and mobile applications, as well as facilitating regulatory approvals for the myCam 1.1 device. CBSC is also working on obtaining FDA clearance for myCam 1.1 to expand its market reach. The company is committed to keeping investors updated on future developments.

CB Scientific (OTCQB:CBSC) has completed regulatory testing for its enhanced myCam cardiac event monitor and submitted a 510(k) application to the FDA for market clearance. The updated design offers reduced power consumption, improved signal quality, and superior materials that cut component lead times by over 50%. The company expects FDA feedback within 90 to 120 days. Following clearance, CBSC aims to market the device in the U.S. and internationally, including Asia and Latin America, enhancing its competitive position in the cardiac monitoring market.

CB Scientific, Inc. (CBSC) has announced a manufacturing partnership with Shenzhen Pump Medical Co., Ltd. to produce its myCam cardiac monitoring device and related software in China. This agreement recognizes Shenzhen Pump as the official manufacturer, compliant with local regulatory standards. CBSC's myCam has demonstrated high performance with over 2.1 million patient interactions and a 99+% efficiency rate in trials. The collaboration aims to expedite the regulatory approval process by the National Medical Products Administration (NMPA).

CB Scientific, Inc. (OTCQB:CBSC) has announced it has entered the regulatory testing phase for its enhanced myCam cardiac event monitoring device, aiming for FDA 510(k) clearance. The new myCam features improved power consumption, lead wire shielding, signal quality, and cost-effective sourcing, maintaining core functionalities while enhancing market competitiveness. Expected submission for FDA approval is imminent, with product delivery plans for Asia, Latin America, and the Middle East upon clearance.

CB Scientific has appointed James Ott as the new Chief Technology Officer, effective immediately. With over 28 years of experience in ambulatory ECG and clinical research, Ott aims to drive technological innovation and business expansion. His extensive background includes leadership roles in product development, regulatory compliance, and significant contributions to U.S. patent submissions. The company, which specializes in non-invasive cardiac monitoring products, expresses confidence in Ott's ability to enhance investor value and improve healthcare solutions.

CB Scientific has successfully uplisted from the OTC Pink Sheets to the OTCQB Venture Market, starting April 6, 2022. This transition is expected to enhance transparency and liquidity for shareholders. CEO Charles Martin stated this achievement will broaden the company's investor outreach. The OTCQB is recognized by the SEC and mandates companies to maintain current disclosure filings and audited financial statements. Additionally, CB Scientific is planning a corporate name change and relocating its domicile to Nevada to leverage favorable tax laws.